Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The phase II study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with radiotherapy in patients with esophageal cancer tumours.
Esophageal
DRUG: Nimotuzumab|RADIATION: Radiotherapy
The rate of AE(adverse event) or toxicity ( Both acute and chronic toxicity will be evaluated.), assement of advers event after using medication based TAAE evaluation form, 3 months
Complete response, 3 months|Partial response (PR), 3 months|Stable disease (SD), 3 months|Progressive disease (PD), 3 months|Median survival time (MST), 2 years|Overall survival (OS), 1 year,2 years
Clinical efficacy has been shown in adult with head and neck cancer. The phase II study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with radiotherapy in patients with esophageal cancer tumours.